LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

Search

CareDx Inc

Cerrado

SectorSanidad

19.2 -1.39

Resumen

Variación precio

24h

Actual

Mínimo

19.05

Máximo

19.88

Métricas clave

By Trading Economics

Ingresos

10M

1.7M

Ventas

13M

100M

P/B

Media del Sector

15.555

76.798

Margen de beneficios

1.674

Empleados

644

EBITDA

11M

6.8M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+12.88% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

274M

1.1B

Apertura anterior

20.59

Cierre anterior

19.2

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

167 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

CareDx Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

18 dic 2025, 23:54 UTC

Acciones populares

Stocks to Watch: Nike, Cassava Sciences, KB Home

18 dic 2025, 23:51 UTC

Ganancias

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18 dic 2025, 23:39 UTC

Principales Movimientos del Mercado

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18 dic 2025, 22:57 UTC

Adquisiciones, fusiones, absorciones

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18 dic 2025, 21:40 UTC

Ganancias

Nike Sales Tick Up, But China Weakness Persists

18 dic 2025, 23:45 UTC

Charlas de Mercado

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18 dic 2025, 23:37 UTC

Charlas de Mercado
Ganancias

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18 dic 2025, 23:36 UTC

Charlas de Mercado

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18 dic 2025, 23:03 UTC

Adquisiciones, fusiones, absorciones

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18 dic 2025, 23:02 UTC

Adquisiciones, fusiones, absorciones

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18 dic 2025, 23:00 UTC

Adquisiciones, fusiones, absorciones

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18 dic 2025, 22:59 UTC

Adquisiciones, fusiones, absorciones

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18 dic 2025, 22:58 UTC

Adquisiciones, fusiones, absorciones

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18 dic 2025, 22:57 UTC

Adquisiciones, fusiones, absorciones

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18 dic 2025, 22:56 UTC

Adquisiciones, fusiones, absorciones

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18 dic 2025, 22:55 UTC

Ganancias

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dic 2025, 21:59 UTC

Ganancias

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dic 2025, 21:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

18 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

18 dic 2025, 21:35 UTC

Ganancias

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18 dic 2025, 21:31 UTC

Ganancias

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Greater China Rev Down 17% >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q EPS 53c >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Apparel Rev $3.91B >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Equipment Rev $550M >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q N Amer Rev $5.63B >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Footwear Rev $7.66B >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Greater China Rev $1.42B >NKE

Comparación entre iguales

Cambio de precio

CareDx Inc previsión

Precio Objetivo

By TipRanks

12.88% repunte

Estimación a 12 Meses

Media 22 USD  12.88%

Máximo 26 USD

Mínimo 18 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CareDx Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

2

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

14.77 / 18.49Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

167 / 374 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat